Evidence map›Paper›PMID 37569294›Full record

ArticleInternational journal of molecular sciences2023

Metabolic Oscillations and Glycolytic Phenotypes of Cancer Cells.

Takashi Amemiya, Kenichi Shibata, Tomohiko Yamaguchi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Takashi AmemiyaGraduate School of Environment and Information Sciences, Yokohama National University (YNU), 79-7 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan.
Kenichi ShibataGraduate School of Environment and Information Sciences, Yokohama National University (YNU), 79-7 Tokiwadai, Hodogaya-ku, Yokohama 240-8501, Japan.
Tomohiko YamaguchiMeiji Institute for Advanced Study of Mathematical Sciences (MIMS), 4-21-1 Nakano, Nakano-ku, Tokyo 164-8525, Japan.

Funding

Japan Society for the Promotion of Science 19H04205Japan Society for the Promotion of Science 20K20631Ministry of Education, Culture, Sports, Science and Technology JPMXP0620335886
6 · The paper itself

Abstract

Cancer cells show several metabolic phenotypes depending on the cancer types and the microenvironments in tumor tissues. The glycolytic phenotype is one of the hallmarks of cancer cells and is considered to be one of the crucial features of malignant cancers. Here, we show glycolytic oscillations in the concentrations of metabolites in the glycolytic pathway in two types of cancer cells, HeLa cervical cancer cells and DU145 prostate cancer cells, and in two types of cellular morphologies, spheroids and monolayers. Autofluorescence from nicotinamide adenine dinucleotide (NADH) in cells was used for monitoring the glycolytic oscillations at the single-cell level. The frequencies of NADH oscillations were different among the cellular types and morphologies, indicating that more glycolytic cancer cells tended to exhibit oscillations with higher frequencies than less glycolytic cells. A mathematical model for glycolytic oscillations in cancer cells reproduced the experimental results quantitatively, confirming that the higher frequencies of oscillations were due to the higher activities of glycolytic enzymes. Thus, glycolytic oscillations are expected as a medical indicator to evaluate the malignancy of cancer cells with glycolytic phenotypes.

Indexed as

NADUterine Cervical NeoplasmsFemaleGlycolysisHeLa CellsHumansPhenotypeTumor MicroenvironmentNADcancer cellsfeedback inhibitionglycolytic oscillationsglycolytic phenotypemalignancymathematical model

Identifiers

PMID37569294
PMCPMC10419005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.